Webinar Recap: How HLA-Compass is Transforming Immunopeptidomics for Safer, Faster Immunotherapy

On May 26, 2025, Dr. Tim Fugmann, Chief Scientific Officer at Alithea Bio, led a live webinar that brought together scientists, biotech researchers, and immunotherapy professionals from around the globe. The session focused on how HLA-Compass, Alithea Bio’s advanced immunopeptidomics platform, is enabling safer, faster, and more precise development of immunotherapies and vaccines

🎯 Key Takeaways from the Webinar

The webinar explored how HLA-Compass is addressing some of immunotherapy’s biggest challenges

• Simplifying Antigen Discovery

Gain actionable, high-confidence data to identify clinically relevant HLA-presented peptides.

• Minimizing Off-Target Toxicity

Improve target specificity for safer, more precise T-cell therapies and cancer immunotherapies.

• Accelerating Vaccine Development

Enable faster preclinical development with scalable, high-throughput HLA ligandome profiling.

🧬 Navigate Peptide Presentation with HLA-Compass

HLA-Compass empowers researchers to

• Rapidly screen for off-targets

• Identify novel HLA-presented targets

• Optimize drug candidate selection

• Uncover peptide presentation across multiple HLA alleles

• Explore all peptides of a gene of interest in both healthy and diseased states

The platform includes

• 4,425 samples

• 1.56 million HLA peptides

• 19 million identifications

• Data spanning 34 healthy organs, 31 tumor types, and 60+ cell lines